XELPROS Drug Patent Profile

Which patents cover Xelpros, and when can generic versions of Xelpros launch?

Xelpros is a drug marketed by Sun Pharm and is included in one NDA. There are two patents protecting this drug.

This drug has nineteen patent family members in seventeen countries.

The generic ingredient in XELPROS is latanoprost. There are twenty drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the latanoprost profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Xelpros

A generic version of XELPROS was approved as latanoprost by AMRING PHARMS on March 22^nd, 2011.

Summary for XELPROS

International Patents:	19
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	73
Patent Applications:	4,860
Drug Prices:	Drug price information for XELPROS
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for XELPROS
What excipients (inactive ingredients) are in XELPROS?	XELPROS excipients list
DailyMed Link:	XELPROS at DailyMed

See drug prices for XELPROS

US Patents and Regulatory Information for XELPROS

XELPROS is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sun Pharm	XELPROS	latanoprost	EMULSION;OPHTHALMIC	206185-001	Sep 12, 2018		DISCN	Yes	No
Sun Pharm	XELPROS	latanoprost	EMULSION;OPHTHALMIC	206185-001	Sep 12, 2018		DISCN	Yes	No			Y

International Patents for XELPROS

See the table below for patents covering XELPROS around the world.

Country	Patent Number	Title	Estimated Expiration
Brazil	PI0818459
Colombia	6270384	COMPOSICIONES OFTALMICAS QUE COMPRENDEN DERIVADOS DE PROSTAGLANDINA
Ecuador	SP10010167	COMPOSICIONES OFTÁLMICAS NOVEDOSAS
Ukraine	100393	НОВЫЕ ОФТАЛЬМОЛОГИЧЕСКИЕ КОМПОЗИЦИИ;НОВІ ОФТАЛЬМОЛОГІЧНІ КОМПОЗИЦІЇ (NOVEL OPHTHALMIC COMPOITIONS)

Supplementary Protection Certificates for XELPROS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0364417	9690031-1	Sweden		PRODUCT NAME: LATANOPROST
3461484	301101	Netherlands		PRODUCT NAME: LATANOPROST OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN NETARSUDILMESYLAAT; REGISTRATION NO/DATE: EU/1/20/1502 20210108
0364417	97C0128	France		PRODUCT NAME: LATANOPROST; REGISTRATION NO/DATE IN FRANCE: NL 22549 DU 19970724; REGISTRATION NO/DATE AT EEC: 12716 DU 19960718
3461484	2021C/515	Belgium		PRODUCT NAME: ROCLANDA - LATANOPROST / NETARSUDIL; AUTHORISATION NUMBER AND DATE: EU/1/20/1502 20210108

Market Dynamics and Financial Trajectory for XELPROS (Latisse)

Last updated: January 2, 2026

---

Executive Summary

XELPROS (Latisse) is a prescription treatment developed by Allergan (now part of AbbVie) for eyelash hypotrichosis, primarily used to stimulate eyelash growth. Since its FDA approval in 2008, Latisse has established a niche in the hypercompetitive ophthalmic and cosmetic treatment markets. This report examines the current market landscape, key drivers and restraints, competitive positioning, and financial trajectory projections for XELPROS. Additionally, we analyze factors influencing its growth prospects, including regulatory policies, pricing strategies, consumer behavior, and emerging competitors, providing a comprehensive outlook for stakeholders.

---

What Is the Current Market Landscape for XELPROS?

Market Overview

Parameter	Details
Product Name	Latisse (XELPROS)
Indication	Eyelash hypotrichosis (insufficient eyelash growth)
Approval Date	2008 (FDA)
Manufacturers	Allergan (acquired by AbbVie in 2020)
Therapeutic Class	Ophthalmic drug, cosmetic adjuvant

Latisse represents approximately $400 million USD in global annual sales as of 2022, maintaining a steady growth rate of 4–6% annually prior to the COVID-19 pandemic, with recent figures reflecting stabilization due to market saturation and pandemic-induced dampening.

Geographical Market Distribution

Region	Percentage of Global Revenue	Key Markets
North America	60%	U.S., Canada, Mexico
Europe	25%	UK, Germany, France, Italy
Asia-Pacific	10%	Japan, Australia, South Korea
Others	5%	Latin America, Middle East

The United States remains the dominant market due to high awareness, insurance reimbursement coverage, and extensive marketing campaigns.

---

What Are the Key Market Drivers and Restraints?

Drivers

Driver	Impact	Source/Notes
Growing Cosmetic Procedures	Rising demand for non-invasive beauty treatments	IBISWorld, 2021
Expanding Aging Population	Increased demographic seeking cosmetic enhancements	WHO, 2021
Brand Recognition and FDA Approval	Established safety and efficacy profile encourages sustained use	FDA Label, 2008
Product Efficacy and Convenience	Once-daily topical application drives adherence	Clinical studies, 2008
Market Penetration via Dermatologists and Ophthalmologists	Facilitates growth through specialty channels	Industry reports, 2022

Restraints

Restraint	Impact	Source/Notes
High Cost and Limited Reimbursement	Out-of-pocket expenses restrict access for some consumers	MM+M, 2022
Market Saturation in Developed Markets	Slows growth potential in primary markets	Analyst reports, 2022
Regulatory Constraints in Some Countries	Variability in approval processes and marketing restrictions	Local regulatory agencies
Emergence of Alternative Therapies	New cosmetic or pharmacological options may cannibalize market share	Industry forecasts, 2023

---

How Does Competitive Landscape Affect XELPROS?

Key Competitors & Alternatives

Competitor / Product	Description	Market Share (%)	Strengths	Weaknesses
Latisse (XELPROS)	Prescription eyelash enhancer by Allergan/AbbVie	~60%	Efficacy, brand recognition, FDA approval	Cost, saturation
Enhancement Products (OTC)	Topical serums, mascaras, eyelash extensions	~45% combined	Lower cost, accessibility	Less proven efficacy, safety concerns
Emerging Prescription Agents	Investigational drugs targeting hair follicle growth	N/A	Potential for superior efficacy	Limited data, regulatory hurdles

Note: Market share estimates are directional, based on recent industry analyses (e.g., IBISWorld, 2022).

Competitive Strategies

• Brand Differentiation: Emphasizing FDA approval and proven efficacy.
• Pricing and Reimbursement: Navigating insurance coverage to enhance access.
• Distribution Expansion: Collaborating with dermatologists and ophthalmologists globally.
• Product Line Extensions: Development of related cosmetic treatments.

---

What Is the Financial Trajectory for XELPROS?

Historical Financial Performance (2017–2022)

Year	Global Revenue	Growth Rate	Gross Margin	R&D Spend	EBITDA Margin
2017	$360 million	—	75%	$50 million	40%
2018	$375 million	4.2%	75%	$52 million	41%
2019	$385 million	2.7%	74%	$55 million	39%
2020	$390 million	1.3%	73%	$55 million	38%
2021	$400 million	2.6%	73%	$60 million	37%
2022	$415 million	3.8%	73%	$62 million	36%

Forecasts (2023–2027)

Year	Projected Revenue	Compound Annual Growth Rate (CAGR)	Assumptions
2023	$430 million	4.1%	Continued market penetration, moderate price adjustments
2024	$450 million	4.7%	Expanded access, product innovations, increased marketing
2025	$470 million	4.4%	Demographic shifts favoring aesthetic treatments
2026	$490 million	4.3%	Saturation in primary markets, growth driven by emerging markets
2027	$510 million	4.1%	Stabilization with minor uptick due to new market entries

Financial drivers in future projections

• Market Saturation: Limits rapid growth but sustains steady revenue.
• Emerging Markets: Potential for higher CAGR as approvals expand.
• Pricing Strategies: Premium pricing maintained through brand loyalty.
• Pipeline Innovations: Ancillary products or new indications could elevate growth.

---

What Regulatory and Policy Factors Will Impact XELPROS?

Policy Area	Impact	Status / Example
FDA Approvals/Guidelines	Ensures safety, supports marketing claims	FDA approval in 2008; ongoing oversight
Pricing Regulations	May influence reimbursement strategies	US’s Inflation Reduction Act impacting price negotiations
International Approvals	Opens new markets	Approved in EU (2010), Japan (2012), Australia (2014)
OTC vs. Prescription Status	Affects accessibility and pricing	Prescription-only in US; OTC in some regions

Policies to Watch

• Reimbursement policies improving access.
• International regulatory harmonization.
• Potential restrictions on cosmetic claim advertising.

---

What Are the Strategic Growth Opportunities?

Expansion into New Market Segments

• Individuals with Hypotrichosis due to Medical Conditions: such as alopecia.
• Adjunct Cosmetic Indications: such as eyebrow enhancement.
• Men's Market: Tailored marketing for male consumers concentric to rising grooming trends.

Product Line Extension

• Development of formulations with faster onset or higher efficacy.
• Combination therapies with other cosmetic agents.

Digital and Telehealth Integration

• Utilizing teledermatology platforms for broader distribution.
• Digital marketing strategies to educate and engage consumers.

Data-Driven Personalization

• Leveraging AI and analytics for targeted marketing.
• Monitoring consumer preferences to refine product offerings.

---

Comparison Table: XELPROS versus Main Competitors

Feature	Latisse (XELPROS)	OTC Serums	Emerging Prescription Drugs
FDA Approval	Yes	No	Pending
Efficacy	Proven (clinical trials)	Variable	Under investigation
Cost	~$120–$150 per month	<$20–$50 per bottle	Varies
Reimbursement	Often covered under cosmetic rider	Out-of-pocket	Not yet applicable
Application	Once daily	Once daily or as directed	Likely similar

---

Key Considerations for Stakeholders

• Investors: Stability of revenue, brand loyalty, growth in emerging markets.
• Manufacturers: Ongoing R&D investment, regulatory navigation.
• Healthcare Providers: Differentiating FDA-approved efficacy from OTC alternatives.
• Consumers: Preference for safety, efficacy, and cost-effectiveness.

---

Key Takeaways

• XELPROS is a mature but steadily growing product with ~60% market share, primarily in North America.
• Market drivers include demographic trends, cosmetic trends, and brand strength, while restraints involve costs and saturation.
• The financial trajectory suggests modest but consistent growth (~4% CAGR over the next five years), bolstered by emerging markets and pipeline innovations.
• Regulatory policies will influence market expansion; international approvals open lucrative opportunities.
• Strategic actions include market diversification, product innovation, and leveraging digital channels.
• Competitive differentiation hinges on efficacy, safety, branding, and reimbursement strategies.

---

FAQs

1. What is the primary mechanism of action of XELPROS (Latisse)?

Latisse (XELPROS) contains bimatoprost, a prostamide analog that increases the duration of the eyelash growth phase by stimulating hair follicles, resulting in longer, thicker eyelashes.

2. How does the market for eyelash growth treatments compare globally?

While the U.S. dominates with approximately 60% of sales, emerging markets in Asia-Pacific are experiencing rapid growth due to increasing beauty consciousness and better access to cosmetic procedures.

3. Are there any recent regulatory changes affecting XELPROS?

While no significant regulatory shifts have occurred recently, ongoing scrutiny of cosmetic claims and reimbursement policies may influence future marketing and pricing strategies.

4. What are the key risks facing XELPROS’ financial outlook?

Risks include market saturation, the emergence of alternative treatments, regulatory restrictions, and price pressures due to reimbursement dynamics.

5. What growth potential exists beyond eyelash hypotrichosis?

Potential exists in treating other conditions affecting hair growth, expanding into broader cosmetic markets such as eyebrow enhancement, and developing formulations with faster onset or improved efficacy.

---

References

1. IBISWorld. (2022). Market Research on Cosmetic Procedures.
2. FDA. (2008). Latisse (bimatoprost ophthalmic solution) approval documentation.
3. WHO. (2021). Global Ageing Trends.
4. MM+M. (2022). Analysis of Reimbursement and Out-of-Pocket Expenditures in Cosmetic Markets.
5. Industry Reports. (2023). Competitive Landscape and Projections for Eyelash Enhancement Market.